{"id":"NCT00005947","sponsor":"Dendreon","briefTitle":"Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","officialTitle":"A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge) for Asymptomatic Metastatic Hormome-Refractory Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1999-11","primaryCompletion":"2004-09","completion":"2004-09","firstPosted":"2004-03-05","resultsPosted":"2010-11-01","lastUpdate":"2010-11-01"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":null,"masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"sipuleucel-T","otherNames":["APC8015, Provenge"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"sipuleucel-T","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer.\n\nPurpose: Randomized phase III trial to determine the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.","primaryOutcome":{"measure":"Time to Objective Disease Progression","timeFrame":"36 months from randomization","effectByArm":[{"arm":"Sipuleucel-T","deltaMin":11.7,"sd":null},{"arm":"Placebo","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.052"},{"comp":"OG000 vs OG001","p":"0.052"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":4},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":["19536890","16809734","35812443","24957547"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":82},"commonTop":["Chills","Fatigue","Pyrexia","Back pain","Nausea"]}}